Cystitis Drug Pipeline Analysis Report 2025
Description
Cystitis is the inflammation of the bladder, often caused by a bacterial urinary tract infection (UTI). It accounts for a significant portion of UTI cases, with approximately 25% of women experiencing recurrent cystitis within six months of an initial infection. The demand for better cystitis drugs is rising due to increasing antibiotic resistance and the need for more effective treatments. The growing focus on innovative therapies, including non-antibiotic options and vaccines, is expected to drive pipeline expansion. Moreover, with advancements in drug development and heightened awareness, the cystitis drug market is likely to grow steadily in the coming years.
Report Coverage
The Cystitis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into cystitis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for cystitis. The cystitis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The cystitis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with cystitis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to cystitis.
Cystitis Drug Pipeline Outlook
Cystitis is the inflammation of the bladder, commonly caused by a bacterial infection, known as a urinary tract infection (UTI). It can also result from irritants like hygiene products or medications. Symptoms include frequent urination, burning sensation, and pelvic discomfort. Women are more prone due to their shorter urethra, which allows bacteria to enter the bladder more easily.
Cystitis is typically treated with antibiotics to eliminate bacterial infections. Mild cases may resolve with increased fluid intake and urinary analgesics. For recurrent cystitis, preventive measures like hygiene adjustments and low-dose antibiotics may be recommended. If caused by irritants, avoiding triggers is crucial. In severe or chronic cases, specialized medical evaluation and tailored therapies may be required for effective management.
Cystitis Epidemiology
Recurrent cystitis affects approximately 25% of women within six months of a simple urinary tract infection (UTI), with higher rates among those with multiple prior UTIs. Chronic cystitis is more common in women, with a prevalence of 3-6% in the United States, affecting 3 to 8 million people. In the United Kingdom, around 50% of women are estimated to have experienced a UTI, a common cause of cystitis.
Cystitis – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of cystitis drug candidates based on several segmentations, including:
By Phase
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total cystitis clinical trials.
Cystitis – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the cystitis pipeline analysis include small molecules, biologics, peptides, gene therapies, vaccines. The cystitis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for cystitis.
Cystitis Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the cystitis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed cystitis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in cystitis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for cystitis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of cystitis drug candidates.
Drug: Raphamin
Raphamin, sponsored by Materia Medica Holding, is currently undergoing Phase III clinical development, where its efficacy and safety are being examined in preventing recurrences of chronic bacterial cystitis. This double-blind, placebo-controlled study involves female patients aged 18 and older. Raphamin is known for its antiviral and antibacterial properties that enhance antibiotic efficacy, even against resistant bacteria, by targeting MHC molecules and boosting immune responses.
Drug: VNX001
VNX001, a proprietary combination of lidocaine and heparin, is being developed by Vaneltix Pharma, Inc. and is currently in a Phase II clinical trial. The study is investigating the treatment's effectiveness for acute moderate to severe bladder pain in patients with interstitial cystitis/bladder pain syndrome (IC/BPS).
Reasons To Buy This Report
The Cystitis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for cystitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into cystitis collaborations, regulatory environments, and potential growth opportunities.
Key Questions Answered in the Cystitis – Pipeline Insight Report
Global Interstitial Cystitis Drugs Market Report and Forecast
Uncomplicated Urinary Tract Infection Epidemiology Forecast
Global Clinical Trials Market
Report Coverage
The Cystitis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into cystitis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for cystitis. The cystitis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The cystitis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with cystitis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to cystitis.
Cystitis Drug Pipeline Outlook
Cystitis is the inflammation of the bladder, commonly caused by a bacterial infection, known as a urinary tract infection (UTI). It can also result from irritants like hygiene products or medications. Symptoms include frequent urination, burning sensation, and pelvic discomfort. Women are more prone due to their shorter urethra, which allows bacteria to enter the bladder more easily.
Cystitis is typically treated with antibiotics to eliminate bacterial infections. Mild cases may resolve with increased fluid intake and urinary analgesics. For recurrent cystitis, preventive measures like hygiene adjustments and low-dose antibiotics may be recommended. If caused by irritants, avoiding triggers is crucial. In severe or chronic cases, specialized medical evaluation and tailored therapies may be required for effective management.
Cystitis Epidemiology
Recurrent cystitis affects approximately 25% of women within six months of a simple urinary tract infection (UTI), with higher rates among those with multiple prior UTIs. Chronic cystitis is more common in women, with a prevalence of 3-6% in the United States, affecting 3 to 8 million people. In the United Kingdom, around 50% of women are estimated to have experienced a UTI, a common cause of cystitis.
Cystitis – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of cystitis drug candidates based on several segmentations, including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Small Molecules
- Biologics
- Peptides
- Gene Therapies
- Vaccines
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total cystitis clinical trials.
Cystitis – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the cystitis pipeline analysis include small molecules, biologics, peptides, gene therapies, vaccines. The cystitis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for cystitis.
Cystitis Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the cystitis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed cystitis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in cystitis clinical trials:
- Vaneltix Pharma, Inc.
- Materia Medica Holding
- Pharmenterprises LLC
- Integrative Therapeutics, Inc.
- Ono Pharmaceutical Co. Ltd.
- HillMed Inc.
- Prevail Infoworks, Inc.
- Lipella Pharmaceuticals, Inc.
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for cystitis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of cystitis drug candidates.
Drug: Raphamin
Raphamin, sponsored by Materia Medica Holding, is currently undergoing Phase III clinical development, where its efficacy and safety are being examined in preventing recurrences of chronic bacterial cystitis. This double-blind, placebo-controlled study involves female patients aged 18 and older. Raphamin is known for its antiviral and antibacterial properties that enhance antibiotic efficacy, even against resistant bacteria, by targeting MHC molecules and boosting immune responses.
Drug: VNX001
VNX001, a proprietary combination of lidocaine and heparin, is being developed by Vaneltix Pharma, Inc. and is currently in a Phase II clinical trial. The study is investigating the treatment's effectiveness for acute moderate to severe bladder pain in patients with interstitial cystitis/bladder pain syndrome (IC/BPS).
Reasons To Buy This Report
The Cystitis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for cystitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into cystitis collaborations, regulatory environments, and potential growth opportunities.
Key Questions Answered in the Cystitis – Pipeline Insight Report
- Which companies/institutions are leading the cystitis drug development?
- What is the efficacy and safety profile of cystitis pipeline drugs?
- Which company is leading the cystitis pipeline development activities?
- What is the current cystitis commercial assessment?
- What are the opportunities and challenges present in the cystitis drug pipeline landscape?
- What is the efficacy and safety profile of cystitis pipeline drugs?
- Which company is conducting major trials for cystitis drugs?
- Which companies/institutions are involved in cystitis collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in cystitis?
Global Interstitial Cystitis Drugs Market Report and Forecast
Uncomplicated Urinary Tract Infection Epidemiology Forecast
Global Clinical Trials Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Cystitis
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: Cystitis
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Cystitis: Epidemiology Snapshot
- 5.1 Cystitis Incidence by Key Markets
- 5.2 Cystitis – Patients Seeking Treatment in Key Markets
- 6 Cystitis: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Cystitis: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Cystitis, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Cystitis Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Cystitis Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: Raphamin
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Other Drugs
- 11 Cystitis Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: VNX001
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Drug: XC243
- 11.2.3 Other Drugs
- 12 Cystitis Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug: Ferumoxytol and Gadobutrol
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Other Drugs
- 13 Cystitis Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Cystitis, Key Drug Pipeline Companies
- 14.1 Vaneltix Pharma, Inc.
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Materia Medica Holding
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Pharmenterprises LLC
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Integrative Therapeutics, Inc.
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Ono Pharmaceutical Co. Ltd.
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 HillMed Inc.
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 Prevail Infoworks, Inc.
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 Lipella Pharmaceuticals, Inc.
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
